Valneva Snares Pfizer For Lyme Disease Vaccine Pact
French Biotech Banks $130m Upfront
Days after inking a COVID-19 collaboration with Dynavax, Valneva has linked up with Pfizer to drive its Lyme disease vaccine VLA15 towards Phase III trials.
You may also be interested in...
Pfizer will invest in partner Valneva’s late-stage Lyme disease jab program, providing much-needed financial support to the French firm which has suffered COVID-19 vaccine sales setbacks.
France's Valneva raises new funds to progress its inactivated vaccine, while Scotland launches a new study into 'long COVID', Takeda reports positive interim results from a Japanese trial with Moderna's mRNA vaccine, a setback for GC's plasma therapy, and Celltrion begins exporting a therapeutic antibody.
The company is hoping for strong efficacy from its inactivated vaccine, boosted by two adjuvants